Skip to main content
Journal cover image

KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas.

Publication ,  Journal Article
Dias-Santagata, D; Selim, MA; Su, Y; Peng, Y; Vollmer, R; Chłopik, A; Tell-Marti, G; Paral, KM; Shalin, SC; Shea, CR; Puig, S; Biernat, W ...
Published in: Br J Dermatol
November 2017

BACKGROUND: Few studies have addressed prognostic markers and none has correlated molecular status and prognosis in vulvar melanomas. OBJECTIVES: To evaluate the clinicopathological features of 95 cases of vulvar melanoma. METHODS: p53, CD117, Ki-67, neurofibromin, brafv600e and nrasq61r immunostains, and molecular analyses by either targeted next-generation or direct sequencing, were performed on available archival materials. RESULTS: Molecular testing detected mutations in KIT (44%), BRAF (25%), NF1 (22%), TP53 (17%), NRAS (9%) and TERT promoter (9%). Co-mutation of KIT and NF1 and of KIT and NRAS were identified in two and one cases, respectively. KIT mutations were significantly associated with better progression-free survival in univariate analyses. In multivariate analyses CD117 expression was significantly associated with better progression-free survival. Tumour thickness was significantly associated with worse progression-free and overall survival, and perineural invasion significantly correlated with reduced melanoma-specific survival and reduced overall survival. Cases were from multiple centres and only a subset of samples was available for molecular testing. CONCLUSIONS: KIT mutations and CD117 overexpression are markers of better progression-free survival. In addition to its prognostic value, molecular testing may identify cases that might respond to targeted agents or immunotherapeutic approaches.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Br J Dermatol

DOI

EISSN

1365-2133

Publication Date

November 2017

Volume

177

Issue

5

Start / End Page

1376 / 1384

Location

England

Related Subject Headings

  • Young Adult
  • Vulvar Neoplasms
  • Retrospective Studies
  • Proto-Oncogene Proteins c-kit
  • Proto-Oncogene Proteins B-raf
  • Prognosis
  • Mutation
  • Middle Aged
  • Melanoma
  • Kaplan-Meier Estimate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dias-Santagata, D., Selim, M. A., Su, Y., Peng, Y., Vollmer, R., Chłopik, A., … Hoang, M. P. (2017). KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol, 177(5), 1376–1384. https://doi.org/10.1111/bjd.15836
Dias-Santagata, D., M. A. Selim, Y. Su, Y. Peng, R. Vollmer, A. Chłopik, G. Tell-Marti, et al. “KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas.Br J Dermatol 177, no. 5 (November 2017): 1376–84. https://doi.org/10.1111/bjd.15836.
Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chłopik A, et al. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017 Nov;177(5):1376–84.
Dias-Santagata, D., et al. “KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas.Br J Dermatol, vol. 177, no. 5, Nov. 2017, pp. 1376–84. Pubmed, doi:10.1111/bjd.15836.
Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chłopik A, Tell-Marti G, Paral KM, Shalin SC, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Ryś J, Marszalek A, Hoang MP. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017 Nov;177(5):1376–1384.
Journal cover image

Published In

Br J Dermatol

DOI

EISSN

1365-2133

Publication Date

November 2017

Volume

177

Issue

5

Start / End Page

1376 / 1384

Location

England

Related Subject Headings

  • Young Adult
  • Vulvar Neoplasms
  • Retrospective Studies
  • Proto-Oncogene Proteins c-kit
  • Proto-Oncogene Proteins B-raf
  • Prognosis
  • Mutation
  • Middle Aged
  • Melanoma
  • Kaplan-Meier Estimate